Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company.
Sensei Biotherapeutics, after recent layoffs and potential wind-down, merged with Faeth Therapeutics and adopted Faeth's Phase 2 cancer drug as its new lead program.
Why it mattersMerger with Faeth secured a Phase 2 oncology asset, prompting investors to reassess Sensei's near-term financing needs.